LLY Eli Lilly (LLY) Q2 FY26 earnings call
Eli Lilly delivered a robust Q2 FY26, marked by significant revenue growth across key products and geographies, leading to an upward revision of full-year guidance. The company is actively expanding market access for its cardiometabolic portfolio, particularly with the Medicare GLP-1 bridge program and international Foundayo approvals. Strategic business development continues to bolster the pipeline in neuroscience, oncology, and infectious diseases, reinforcing a commitment to addressing unmet medical needs and driving long-term growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.